Appendix B - 60-Day Federal Register Notice

16369

Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices
complete the questionnaire with the
instructions provided.
The activity-based cost data provided
by the 68 grantees will be used to
evaluate the programs to ensure the
most appropriate use of limited program
resources. Performing an assessment of
the resources expended on NBCCEDP
will provide valuable information to the
CDC and it partners for improving
program efficiency within the various
components of the NBCCEDP including
screening, case management, outreach,
and overall management. The detailed

of the Minimum Data Elements (MDEs),
the additional burden on grantees to
provide the requested cost data will be
modest. If future cost data collection
efforts are undertaken, the response
burden would be further reduced
because the infrastructure established to
capture the data is already in place.
There are no costs to respondents
except their time to participate in the
survey.

cost data will allow CDC to assess the
costs of the various program
components, identify factors that impact
average cost, perform cost-effectiveness
analysis and develop a resource
allocation tool. The collection and
analysis of the cost data will allow CDC
to utilize a more systematic process to
allocate program resources based on
grantees’ past performance, level of
efficiency, and future needs.
Since information on screening and
diagnosis volumes (the effectiveness
measures) are already collected as part

ESTIMATED ANNUALIZED BURDEN HOURS
Number
responses per
respondent

Average
burden per
response
(in hours)

Total burden
hours

Form name

Program Director ...............................
Business Manager ............................
Data Manager ...................................

Cost Assessment Tool .....................
...........................................................
...........................................................

68
68
68

1
1
1

4
4
14

272
272
952

Total ...........................................

...........................................................

........................

........................

........................

1,496

Dated: March 28, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–6275 Filed 4–3–07; 8:45 am]

Centers for Disease Control and
Prevention

practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.

[60Day–07–06AY]

Proposed Project

Proposed Data Collections Submitted
for Public Comment and
Recommendations

Evaluation of the Spanish-Language
Campaign ‘‘Good Morning Arthritis,
Today you will not defeat us.’’—New—
National Center for Chronic Disease
Prevention and Health Promotion
(NCCDPHP), Centers for Disease Control
and Prevention (CDC).

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

jlentini on PROD1PC65 with NOTICES

Number of
respondents

Type of respondent

In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–5960 and
send comments to Joan Karr, CDC
Acting Reports Clearance Officer, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an e-mail to
omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have

VerDate Aug<31>2005

17:57 Apr 03, 2007

Jkt 211001

Background and Brief Description
Arthritis affects nearly 43 million
Americans, or about one in every six
people, and is the leading cause of
disability among adults in the United
States. Because of the broad public
health impact of this disease, the
Centers for Disease Control and
Prevention (CDC) developed the
National Arthritis Action Plan in 1998
as a comprehensive approach to
reducing the burden of arthritis in the
United States.
As part of its efforts to implement the
National Arthritis Action Plan, CDC
developed and tested a health
communications campaign promoting
physical activity among Caucasian and

PO 00000

Frm 00045

Fmt 4703

Sfmt 4703

African-American adults with arthritis.
In 2003–2004, CDC developed a similar
campaign for Spanish-speaking people
with arthritis. Hispanic populations
have a slightly lower prevalence rate of
self-reported, doctor-diagnosed arthritis,
but Hispanics with arthritis report
greater work limitations, and higher
rates of severe pain than do Caucasian
populations with arthritis.
The Spanish-language campaign,
Good Morning Arthritis, Today you will
not defeat us, is designed to reach
Spanish speaking adults with arthritis
who are aged 45–64, who have high
school education or less, and whose
annual income is less than $35,000. The
key message elements of the Spanish
language health communications
campaign are similar to its English
counterpart, as are the campaign
objectives and materials. The campaign
objectives are to increase target
audience members’ (1) Beliefs about
physical activity as an arthritis
management strategy (there are ‘‘things
they can do’’ to make arthritis better,
and physical activity is an important
part of arthritis management); (2)
Knowledge of the benefits of physical
activity and appropriate physical
activity for people with arthritis; (3)
Confidence in their ability to be
physically active, and (4) Trial of
physical activity behaviors. Based on
formative research, campaign materials
refer to exercise instead of physical
activity. Campaign materials include;
print ads, 30- and 60-second radio ads
and public service announcements, and
desktop displays with brochures for

E:\FR\FM\04APN1.SGM

04APN1

16370

Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices

pharmacies, doctors’ offices, and
community centers.
In the Fall of 2005, the Spanish
language campaign was pilot tested by
5 state health departments that receive
funding from CDC for their arthritis
programs. CDC will eventually
disseminate these materials to all 36

CDC will conduct an evaluation of the
impact of the Spanish language health
communications campaign on the
exercise/physical activity-related
attitudes, beliefs, and behaviors among
the target audience of Spanish-speaking
people with arthritis. There are no costs
to the respondents other than their time.

CDC-funded states. The 5 preliminary
pilot tests focused on reach and
exposure; a more thorough evaluation is
necessary to assess impact of the
campaign. This information will be used
to guide the public health practice of the
36 state arthritis programs and their
partners.

ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)

Total burden
(in hours)

Screening Survey ............................................................................................
Telephone Survey ............................................................................................

12,000
2,500

1
1

2/60
15/60

400
625

Total ..........................................................................................................

........................

........................

........................

1,025

Dated: March 28, 2007.
Joan F. Karr,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–6276 Filed 4–3–07; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Technical
Support for Birth Defects and
Developmental Disabilities Prevention
Education Efforts, Contract Solicitation
Number (CSN) 2006–N–08835

jlentini on PROD1PC65 with NOTICES

Number of
responses per
respondent

Number of
respondents

Respondents

In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned SEP:
Time and Date: 12 p.m.–3 p.m., April
30, 2007 (Closed).
Place: Teleconference, Centers for
Disease Control and Prevention, 1600
Clifton Road, NE., Atlanta, GA 30333.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in Section
552b(c)(4) and (6), Title 5 U.S.C., and
the Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters to be Discussed: The meeting
will include the review, discussion, and
evaluation of applications received in
response to CSN 2006–N–08835,
‘‘Technical Support for Birth Defects
and Developmental Disabilities
Prevention Education Efforts.’’

VerDate Aug<31>2005

17:57 Apr 03, 2007

Jkt 211001

For Further Information Contact:
Christine Morrison, Ph.D., Scientific
Review Administrator, Centers for
Disease Control and Prevention, 1600
Clifton Road NE., Mailstop D72, Atlanta,
GA 30333, Telephone 404.639.3098.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: March 28, 2007.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–6270 Filed 4–3–07; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Preparation for International
Conference on Harmonisation
Meetings in Brussels, Belgium; Public
Meeting
AGENCY:

Food and Drug Administration,

HHS.
ACTION:

Notice of meeting.

SUMMARY: The Food and Drug
Administration (FDA) is announcing a
public meeting entitled ‘‘Preparation for
ICH Meetings in Brussels, Belgium’’ to
provide information and receive
comments on the International
Conference on Harmonisation (ICH) as
well as the upcoming meetings in
Brussels, Belgium. The topics to be
discussed are the topics for discussion
at the forthcoming ICH steering

PO 00000

Frm 00046

Fmt 4703

Sfmt 4703

committee meeting. The purpose of the
meeting is to solicit public input prior
to the next steering committee and
expert working groups meetings in
Brussels, Belgium May 5–10, 2007, at
which discussion of the topics
underway and the future of ICH will
continue.
Date and Time: The meeting will be
held on Friday April 6, 2007, from 3:30
p.m. to 5 p.m.
Location: The meeting will be held at
5600 Fishers Lane, third floor,
Conference Room G, Rockville, MD
20857. For security reasons, all
attendees are asked to arrive no later
than 3:20 p.m., as you will be escorted
from the front entrance of 5600 Fishers
Lane to Conference Room G.
Contact Person: Michelle Limoli,
Office of the Commissioner (HFG–1),
Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857,
301–827–0908, e-mail:
michelle.limoli@fda.hhs.gov, FAX: 301–
827–0003.
Registration and Requests for Oral
Presentations: Send registration
information (including name, title, firm
name, address, telephone, and fax
number), written material, and requests
to make oral presentations, to the
contact person by April 5, 2007.
If you need special accommodations
due to a disability, please contact
Michelle Limoli as soon as possible.
SUPPLEMENTARY INFORMATION: The ICH
was established in 1990 as a joint
regulatory/industry project to improve,
through harmonization, the efficiency of
the process for developing and
registering new medicinal products in
Europe, Japan, and the United States
without compromising the regulatory
obligations of safety and effectiveness.
In recent years, many important
initiatives have been undertaken by
regulatory authorities and industry

E:\FR\FM\04APN1.SGM

04APN1